Gut Microbiota Signatures in Colorectal Cancer as a Potential Diagnostic Biomarker in the Future: A Systematic Review.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Colorectal Neoplasms*/diagnosis ; Colorectal Neoplasms*/microbiology ; Gastrointestinal Microbiome* ; Biomarkers, Tumor* ; Dysbiosis*/microbiology ; Dysbiosis*/diagnosis; Humans

The gut microbiota has acquired significant attention in recent years for its potential as a diagnostic biomarker for colorectal cancer (CRC). In this literature review, we looked at the studies exploring alterations in gut microbiota composition associated with CRC, the potential mechanisms linking gut dysbiosis to CRC development, and the diagnostic approaches utilizing gut microbiota analysis. Our research has led to the conclusion that individuals with CRC often display alterations in their gut microbiota composition compared to healthy individuals. These alterations can include changes in the diversity, abundance, and type of bacteria present in the gut. While the use of gut microbiota as a diagnostic biomarker for CRC holds promise, further research is needed to validate its effectiveness and standardize testing protocols. Additionally, considerations such as variability in the microbiota composition among individuals and potential factors must be addressed before microbiota-based tests can be widely implemented in clinical practice.

Medicine (Baltimore). 2021 Jan 8;100(1):e24059. (PMID: 33429768)
Onco Targets Ther. 2020 Jan 21;13:635-646. (PMID: 32021305)
Front Immunol. 2022 Nov 08;13:1030745. (PMID: 36426359)
Gut Pathog. 2013 Mar 07;5(1):2. (PMID: 23497613)
Cell Host Microbe. 2021 Oct 13;29(10):1589-1598.e6. (PMID: 34536346)
Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):111-128. (PMID: 29018272)
Gastroenterol Rep (Oxf). 2018 Feb;6(1):1-12. (PMID: 29479437)
Int J Mol Sci. 2021 Jun 10;22(12):. (PMID: 34200820)
J Pers Med. 2023 Nov 13;13(11):. (PMID: 38003917)
Malays J Med Sci. 2020 Jul;27(4):9-21. (PMID: 32863742)
Crit Rev Oncol Hematol. 2021 Mar;159:103232. (PMID: 33497759)
Nutr Res Pract. 2023 Aug;17(4):616-630. (PMID: 37529264)
Public Health. 2022 Oct;211:97-104. (PMID: 36063775)
Microorganisms. 2024 May 30;12(6):. (PMID: 38930493)
Nat Med. 2019 Apr;25(4):679-689. (PMID: 30936547)
J Eval Clin Pract. 2017 Jun;23(3):631-641. (PMID: 28026076)
Front Cell Dev Biol. 2022 Jun 02;10:916961. (PMID: 35721506)
Int J Mol Sci. 2024 Mar 21;25(6):. (PMID: 38542513)
Nat Med. 2019 Apr;25(4):667-678. (PMID: 30936548)
J Lipid Res. 2015 Jun;56(6):1085-99. (PMID: 25210150)
Int J Colorectal Dis. 2020 Aug;35(8):1413-1421. (PMID: 32556652)
Front Cell Infect Microbiol. 2023 Jan 10;12:1054808. (PMID: 36704106)
J Clin Gastroenterol. 2011 Apr;45(4):297-300. (PMID: 21301355)
Oncol Rev. 2023 May 22;17:10576. (PMID: 37284188)
JAMA Oncol. 2020 Mar 1;6(3):e194489. (PMID: 31855256)
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):269-276. (PMID: 28404156)
Cancers (Basel). 2023 Feb 10;15(4):. (PMID: 36831495)
PLoS One. 2013;8(2):e56964. (PMID: 23457644)
Eur J Cancer Prev. 2017 May;26(3):201-211. (PMID: 26945285)
Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
Int J Mol Sci. 2023 Apr 28;24(9):. (PMID: 37175726)
Gut. 2017 Jan;66(1):70-78. (PMID: 26408641)
Int J Colorectal Dis. 2020 Jun;35(6):985-995. (PMID: 32314192)
Infect Dis Clin North Am. 2021 Sep;35(3):827-839. (PMID: 34362546)
Cell. 2014 Mar 27;157(1):121-41. (PMID: 24679531)
Nutrients. 2020 Mar 11;12(3):. (PMID: 32168964)
Am J Chin Med. 2021;49(4):805-828. (PMID: 33827382)
Nature. 2024 Apr;628(8007):424-432. (PMID: 38509359)
Am J Surg. 2022 Jul;224(1 Pt B):323-331. (PMID: 35210062)
Cancer Prev Res (Phila). 2014 Nov;7(11):1112-21. (PMID: 25104642)
Gut. 2017 Apr;66(4):633-643. (PMID: 26992426)
Curr Colorectal Cancer Rep. 2014;10:45-54. (PMID: 24659930)
J Surg Res. 2023 Feb;282:53-64. (PMID: 36257164)
Front Cell Infect Microbiol. 2022 Nov 29;12:1020583. (PMID: 36523635)
Crit Rev Oncol Hematol. 2018 Sep;129:91-101. (PMID: 30097241)
Nutrients. 2023 Aug 02;15(15):. (PMID: 37571367)
J Med Libr Assoc. 2018 Oct;106(4):420-431. (PMID: 30271283)
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. (PMID: 36856579)
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1229-1240.e5. (PMID: 33524598)
Mol Diagn Ther. 2017 Apr;21(2):153-165. (PMID: 27878475)
Oxid Med Cell Longev. 2016;2016:2353560. (PMID: 27433286)
Ann Med. 2023;55(2):2281662. (PMID: 38113874)
Commun Biol. 2024 Jan 5;7(1):24. (PMID: 38182885)
Cancers (Basel). 2022 Mar 29;14(7):. (PMID: 35406504)
Nat Med. 2019 Jun;25(6):968-976. (PMID: 31171880)
Can J Infect Dis Med Microbiol. 2021 Nov 9;2021:2131787. (PMID: 34795808)
J Gastrointestin Liver Dis. 2023 Mar 31;32(1):30-38. (PMID: 37004230)
Gut. 2018 Aug;67(8):1454-1463. (PMID: 28988196)
Nat Commun. 2021 May 24;12(1):3063. (PMID: 34031391)
J Med Life. 2012 Oct-Dec;5(Spec Issue):152-159. (PMID: 31803304)
Mol Syst Biol. 2014 Nov 28;10:766. (PMID: 25432777)

Keywords: biomarker; colorectal cancer; gut microbiota; microbiota composition

0 (Biomarkers, Tumor)

Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240729

20240729

PMC11276678

10.3390/ijms25147937

39063179